Table 3.

Effect of dFEV₁ on the HR for Exacerbation

Inclusion	No. of Trials	No. of Comparisons	No. of Subjects	Slope (b) Estimate (95% CI)	HR = Exp(b) Estimate (95% CI)	P	R2
All studies	39	65	73,475	–0.23 (–0.28 to –0.18)	0.79 (0.74 to 0.83)	< .001	0.85
Only two arms	19	19	27,578	–0.27 (–0.43 to –0.12)	0.74 (0.64 to 0.86)	< .001	0.65
BD only	20	34	53,308	–0.25 (–0.32 to –0.19)	0.77 (0.72 to 0.82)	< .001	0.88
ICS only	12	17	18,415	–0.21 (–0.37 to –0.04)	0.81 (0.69 to 0.96)	.013	0.63
PDE4 only	6	6	7,349	0.06 (–1.28 to 1.41)	1.06 (0.28 to 4.11)	.926	0.00
Non-BD	22	31	27,750	–0.17 (–0.28 to –0.07)	0.84 (0.76 to 0.93)	< .001	0.68
≥ 1 Exacerbation in previous year	13	21	19,663	–0.26 (–0.37 to –0.15)	0.77 (0.69 to 0.86)	< .001	0.75

For this analysis, our model is ln(HR) = a + b*dTreat, where HR = hazard ratio. The unit for dTreat is 100 mL. See Table 1 legend for expansion of other abbreviations.